Halozyme Reports Strong Q3 2026 Results with Significant Revenue Growth and Raised Guidance
Halozyme (HALO) reported robust third-quarter 2026 financial results, headlined by a 39% year-over-year increase in total revenue to $493 million. This growth was primarily fueled by record royalty revenues of $341 million, driven by high demand for ENHANZE partner products such as VYVGART Hytrulo and DARZALEX subcutaneous. The company's adjusted EBITDA also saw a significant 35% increase, reaching $336.2 million. Following these strong results, Halozyme raised its full-year 2026 guidance for revenue, royalty income, adjusted EBITDA, and non-GAAP diluted EPS. The company maintains a strong liquidity position with $1.08 billion in cash and marketable securities, supported by recent capital raises. Strategic focus remains on the Hypercon platform and expanding clinical pipelines to drive long-term value.
Topics: EBITDA EPS guidance raise revenue growth royalty revenue